Insights

1. Why Method-of-Use Patents Now Control More Revenue Than Compound Patents A structural shift has occurred in pharmaceutical patent litigation […]

I. Executive Summary The U.S. pharmaceutical patent system is not a passive legal framework. It is an engineered adversarial machine,

A comprehensive technical guide to building event-driven pharmaceutical cost forecasts using patent expiration data, FDA exclusivity calendars, Paragraph IV litigation

The global generic drug market will cross $700 billion by the early 2030s. Individual companies inside it are getting crushed.

1. Why the Patent Portfolio Is the Real Balance Sheet A company’s income statement tells you what it earned last

Section 1: The Hatch-Waxman Architecture: Why Conflict Is a Feature, Not a Bug Most people who cover pharmaceutical equities understand

Generic drug development has a public relations problem. The phrase ‘generic drug’ suggests a simple act of copying, the pharmaceutical

Every blockbuster drug runs on a clock it cannot stop. The question is whether your legal and portfolio teams know

Section 1: Executive Summary and Key Takeaways Drug development is a decade-plus, multi-billion-dollar bet made in almost complete informational darkness.